XML 29 R4.htm IDEA: XBRL DOCUMENT v3.24.0.1
Consolidated Statements of Operations - USD ($)
shares in Thousands, $ in Thousands
 12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Operating expenses:      
Research and development, net of grant reimbursement $ 89,423 $ 68,032 $ 24,813
General and administrative 16,534 11,988 8,055
Total operating expenses 105,957 80,020 32,868
Operating loss (105,957) (80,020) (32,868)
Interest income 7,833 2,777 49
Other income, net 907 997 434
Net loss $ (97,217) $ (76,246) $ (32,385)
Net loss per share, basic and diluted (in dollars per share) $ (2.32) $ (1.9) $ (0.82)
Shares used in computing net loss per share, basic and diluted (in shares) 41,932 40,202 39,405